Stocks and Investing
Stocks and Investing
Mon, July 18, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jay Olson Maintained (BIIB) at Buy with Increased Target to $230 on, Jul 18th, 2022
Jay Olson of Oppenheimer, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $225 to $230 on, Jul 18th, 2022.
Jay has made no other calls on BIIB in the last 4 months.
There are 7 other peers that have a rating on BIIB. Out of the 7 peers that are also analyzing BIIB, 2 agree with Jay's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $210 on, Wednesday, May 4th, 2022
- Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022
These are the ratings of the 5 analyists that currently disagree with Jay
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $251 on, Wednesday, May 4th, 2022
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $285 on, Wednesday, May 4th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $270 on, Thursday, April 21st, 2022
- Mohit Bansal of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $265 on, Monday, April 18th, 2022
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $262 on, Friday, April 8th, 2022
Contributing Sources